Financial reports
10-Q
2024 Q2
Quarterly report
13 Feb 24
10-Q
2024 Q1
Quarterly report
13 Nov 23
10-K
2023 FY
Annual report
14 Sep 23
10-Q
2023 Q3
Quarterly report
11 May 23
10-Q
2023 Q2
Quarterly report
10 Feb 23
10-Q
2023 Q1
Quarterly report
9 Nov 22
10-K
2022 FY
Annual report
15 Sep 22
10-Q
2022 Q3
Quarterly report
12 May 22
10-Q
2022 Q2
Quarterly report
9 Feb 22
10-Q
2022 Q1
Quarterly report
12 Nov 21
Current reports
8-K
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
25 Apr 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Other Events
22 Feb 24
8-K
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
13 Feb 24
8-K
Unregistered Sales of Equity Securities
29 Jan 24
8-K
Plans to report topline data mid-second quarter 2024
14 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Nov 23
8-K
Rezolute Reports First Quarter Fiscal 2024 Results
13 Nov 23
8-K
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
18 Oct 23
Registration and prospectus
S-3/A
Shelf registration (amended)
22 Nov 23
S-3
Shelf registration
15 Nov 23
S-8
Registration of securities for employees
7 Nov 22
S-3
Shelf registration
28 Oct 22
424B3
Prospectus supplement
1 Jul 22
S-3/A
Shelf registration (amended)
28 Jun 22
S-3
Shelf registration
17 Jun 22
424B5
Prospectus supplement for primary offering
20 May 22
424B5
Prospectus supplement for primary offering
20 May 22
424B5
Prospectus supplement for primary offering
2 May 22
Proxies
DEF 14A
Definitive proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
DEF 14A
Definitive proxy
16 May 22
PRE 14A
Preliminary proxy
6 May 22
DEF 14A
Definitive proxy
28 Apr 21
PRE 14A
Preliminary proxy
12 Apr 21
DEF 14A
Definitive proxy
23 Sep 19
PRER14A
Preliminary revised proxy
16 Sep 19
PRE 14A
Preliminary proxy
6 Sep 19
Other
EFFECT
Notice of effectiveness
30 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
UPLOAD
Letter from SEC
20 Nov 23
EFFECT
Notice of effectiveness
10 Nov 22
CORRESP
Correspondence with SEC
7 Nov 22
UPLOAD
Letter from SEC
4 Nov 22
EFFECT
Notice of effectiveness
5 Jul 22
CORRESP
Correspondence with SEC
29 Jun 22
EFFECT
Notice of effectiveness
25 Jun 21
EFFECT
Notice of effectiveness
24 Jun 21
Ownership
4
BRIAN KENNETH ROBERTS
29 Mar 24
4
Change in insider ownership
19 Mar 24
4
Daron Evans
19 Mar 24
4
BRIAN KENNETH ROBERTS
18 Mar 24
4/A
BRIAN KENNETH ROBERTS
18 Mar 24
4
Young-Jin Kim
14 Mar 24
SC 13G
Nantahala Capital Management, LLC
11 Mar 24
4
BRIAN KENNETH ROBERTS
11 Mar 24
4
Daron Evans
8 Mar 24
4
Nevan C Elam
28 Feb 24